A Phase II study of St. John's Wort for smoking cessation

Complementary Therapies in Medicine

Volumn 14, Issue 3, 2006, Pages 175-184

  Lawvere, Silvana ^a   Mahoney, Martin C ^a   Cummings, K Michael ^a   Kepner, James L ^a   Hyland, Andrew ^a   Lawrence, David D ^a   Murphy, Jill M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Clinical trial; Herbal agent; Hypericum; Pharmacotherapy; Prevention; Smoking

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; HYPERICUM PERFORATUM EXTRACT; NICOTINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CENTER; CIGARETTE SMOKING; CLINICAL TRIAL; CONSTIPATION; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DIZZINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PHYSICAL EXAMINATION; POSTAL MAIL; SEIZURE; SELF REPORT; SMOKING CESSATION; TELEPHONE; TOBACCO DEPENDENCE; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT CHANGE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; HUMANS; HYPERICUM; MALE; MIDDLE AGED; PLANT EXTRACTS; SMOKING CESSATION;

EID: 33746904826     PISSN: 09652299     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctim.2006.01.007     Document Type: Article

References (43)

1. Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., and Melchart D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ 313 7052 (1996) 253-258
2. Wiley J.L., LaVecchia K.L., Martin B.R., and Damaj M.I. Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 10 2 (2002) 129-135
3. Neary J.T., and Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 816 2 (1999) 358-363
4. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., et al. A comparison of sustained-release bupropion and placebo for smoking cessation [see comments]. N Engl J Med 337 17 (1997) 1195-1202
5. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 9 (1999) 685-691
6. Wilkinson M.J., and Barczak P. Psychiatric screening in general practice: comparison of the general health questionnaire and the hospital anxiety depression scale. J R Coll Gen Pract 38 312 (1988) 311-313
7. Speilberger C. Manual for the state-trait anxiety inventory. 2nd ed. (1983), Consulting Psychologists Press, Palo Alto, CA
8. Kerb R., Brockmoller J., Staffeldt B., Ploch M., and Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 40 9 (1996) 2087-2093
9. Sommer H., and Harrer G. Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients. J Geriatr Psychiatry Neurol 7 Suppl. 1 (1994) S9-S11
10. Harrer G., Hubner W.D., and Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol 7 Suppl. 1 (1994) S24-S28
11. Harrer G., and Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum. J Geriatr Psychiatry Neurol 7 1 (1994) S6-S8
12. Martinez B., Kasper S., Ruhrmann S., and Moller H.J. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 7 Suppl. 1 (1994) S29-S33
13. Vorbach E.U., Hubner W.D., and Arnoldt K.H. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: Randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol 7 Suppl. 1 (1994) S19-S23
14. Vorbach E.U., Arnoldt K.H., and Hubner W.D. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 30 Suppl. 2 (1997) 81-85
15. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients-a controlled 6-week clinical trial. Pharmacopsychiatry 2 (1997) 77-80
16. Ernst E. St. John's Wort, an Antidepressant? A systematic criteria based overview. Phytotherapy 2 (1995) 67-71
17. Volz H., and Hansel R. Hypericum as a plant antidepressant. Psychopharmakotherapie 2 (1995) 1-9
18. Fiore M.C. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respiratory Care 45 10 (2000) 1196-1199
19. Shiffman S.M., and Jarvik M.E. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology (Berl) 50 1 (1976) 35-39
20. Middleton E.T., and Morice A.H. Breath carbon monoxide as an indication of smoking habit. Chest 117 3 (2000) 758-763
21. Kepner J., and Chang M. On the maximum total sample size of a group sequential test about binomial proportions. Stat Probability Letts 62 1 (2003) 87-92
22. Kepner J., and Chang M. Samples of exact k-stage group sequential designs for Phase II and Pilot studies. Control Clin Trials 25 3 (2004) 326-333
23. Hollander M., and Wolfe D. Nonparametric statistical methods (1999), John Wiley and Sons
24. Kepner J., and Robinson D. A distribution-free rank test for ordered alternatives in randomized complete block designs. J Am Stat Assoc 79 385 (1984) 212-217
25. Zhu S., Melcer T., Sun J., Rosbrook B., and Pierce J.P. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 18 4 (2000) 305-311
26. Ossip-Klein D.J., Bigelow G., Parker S.R., Curry S., Hall S., and Kirkland S. Classification and assessment of smoking behavior. Health Psychol 5 Suppl. (1986) 3-11
27. Hughes J.R., Keely J.P., Niaura R.S., Ossip-Klein D.J., Richmond R.L., and Swan G.E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 5 1 (2003) 13-25
28. Barnes J., Barber N., Wheatley D., and Williamson E. A pilot randomized, open, uncontrolled, clinical study of two dosages of St John's Wort (Hypericum perforatum L) Herb Extract (LI-160) as an Aid to Motivational/Behavioural Support in Smoking Cessation. Planta Medica 4 (2006) 378-382
29. Becker B, Brock B, Carmona-Barros R, St. John's Wort Oral Spray Reduces Withdrawal Symptoms during Quitting Smoking. In: Society for Research on Nicotine and Tobacco; 2003 (abstract published in 2003 conference proceedings).
30. Calapai G., Crupi A., Firenzuoli F., Inferrera G., Squadrito F., Parisi A., et al. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry 34 2 (2001) 45-49
31. Catania M.A., Firenzuoli F., Crupi A., Mannucci C., Caputi A.P., and Calapai G. Hypericum perforatum attenuates nicotine withdrawal signs in mice. Psychopharmacology (Berl) 169 2 (2003) 186-189
32. Velicer W.F., Hughes S.L., Fava J.L., Prochaska J.O., and DiClemente C.C. An empirical typology of subjects within stage of change. Addict Behav 20 3 (1995) 299-320
33. Gaster B., and Holroyd J. St John's Wort for depression: a systematic review. [Review] [40 refs]. Arch Intern Med 160 2 (2000) 152-156
34. Schrader E., Meier B., and Brattstrom A. Hypericum treatment of mild-moderate depression in a prospective, double-blind, randomized, placebo controlled, multicentre study. Human Psychopharmacol Clin Exp 13 (1998) 163-169
35. Schulz V., Hansel R., and Tyler V. Rational phytotherapy (1998), Springer, Berlin
36. Brockmoller J., Reum T., Bauer S., Kerb R., Hubner W.D., and Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 2 (1997) 94-101
37. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Therap 294 1 (2000) 88-95
38. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's Wort) in major depressive disorder: a randomized controlled trial. JAMA 2002;287(14):1807-14.
39. Barone G.W., Gurley B.J., Ketel B.L., Lightfoot M.L., and Abul-Ezz S.R. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 34 9 (2000) 1013-1016
40. Karliova M., Treichel U., Malago M., Frilling A., Gerken G., and Broelsch C.E. Interaction of Hypericum perforatum (St. John's Wort) with cyclosporin: a metabolism in a patient after liver transplantation. J Hepatol 33 5 (2000) 853-855
41. Hammerness P., Basch E., Ulbricht C., Barrette E.P., Foppa I., Basch S., et al. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44 4 (2003) 271-282
42. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.S., et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290 11 (2003) 1500-1504
43. Kaptchuk T.J., and Eisenberg D.M. Varieties of healing 1: medical pluralism in the United States. Ann Intern Med 135 3 (2001) 189-195